In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Shaping The Medical Industry (11/2011)

Executive Summary

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

You may also be interested in...



Ways To Find And Nurture Young, Diverse Talent In Pharma

On this podcast, In Vivo's Jo Shorthouse is joined by Rebekah Martin, senior vice president of reward, inclusion, and talent acquisition at AstraZeneca to talk about the ways that pharma should be encouraging a diverse and inclusive team of young talent, and that strong connection between diversity of thought and innovation.

Snapshot: September Highlights

A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.

Mifepristone Access Swings In The Balance In Post-Roe World

The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV003721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel